Cognitive and psychiatric comorbidities in neuromyelitis optica

Moore, Pascale; Methley, Abigail; Pollard, Catherine; Mutch, Kerry; Hamid, Shahd; Elsone, Liene; Jacob, Anu

doi:10.1016/j.jns.2015.11.031

Cited by 68 publications

(82 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been reported that more than half of patients with NMOSD have cognitive impairment, [66][67][68][69][70] especially in terms of memory, executive function, attention, speed of information processing deficits and verbal fluencies. 66,68,71 Furthermore, the volume of white matter is decreased in NMOSD patients with cognitive impairment compared with that in NMOSD patients without cognitive impairment, and correlations between cognitive tests performance and white matter volume were detected.…”

Section: Cognition In Nmosdmentioning

confidence: 99%

Cognitive impairment as one of the important non‐motor symptoms in multiple sclerosis and neuromyelitis optica spectrum disorders

Niino

Miyazaki

2019

Clinical & Exp Neuroim

View full text Add to dashboard Cite

Cognitive impairment is one of the most important non-physical symptoms of patients with multiple sclerosis (MS), and few studies have reported on cognitive impairments in patients with neuromyelitis optica spectrum disorders. Adequate batteries are required to assess cognitive function in MS, and cognitive impairments in patients with MS are likely not adequately evaluated. As cognitive impairment usually affects employment status and activities of daily living in patients with MS and neuromyelitis optica spectrum disorders, the effect of this symptom on daily activities should be closely examined. The present review focuses on the prevalence and characteristics of cognitive impairments in patients with MS and neuromyelitis optica spectrum disorders, as well as the methods used to evaluate cognitive function in such patients.

show abstract

Section: Cognition In Nmosdmentioning

confidence: 99%

Cognitive impairment as one of the important non‐motor symptoms in multiple sclerosis and neuromyelitis optica spectrum disorders

Niino

Miyazaki

2019

Clinical & Exp Neuroim

View full text Add to dashboard Cite

show abstract

“…8–10 However, recent studies have reported a high prevalence of depression within this population and have claimed that patients with NMOSD present with depression severity comparable to that experienced by patients with multiple sclerosis. 11–13 Due to the low prevalence of NMOSD, 14,15 previous studies have employed smaller samples and international comparisons are currently missing. Therefore, it is imperative to investigate the elements of depression among patients with NMOSD within a larger multicenter cohort.…”

mentioning

confidence: 99%

Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder

Chavarro

Mealy

Simpson

et al. 2016

Neurol Neuroimmunol Neuroinflamm

View full text Add to dashboard Cite

Objective:To investigate depression frequency, severity, current treatment, and interactions with somatic symptoms among patients with neuromyelitis optica spectrum disorder (NMOSD).Methods:In this dual-center observational study, we included 71 patients diagnosed with NMOSD according to the International Panel for NMO Diagnosis 2015 criteria. The Beck Depression Inventory (BDI) was classified into severe, moderate, or minimal/no depressive state category. We used the Fatigue Severity Scale to evaluate fatigue. Scores from the Brief Pain Inventory and the PainDETECT Questionnaire were normalized to estimate neuropathic pain. Psychotropic, pain, and immunosuppressant medications were tabulated by established classes.Results:Twenty-eight percent of patients with NMOSD (n = 20) had BDI scores indicative of moderate or severe depression; 48% of patients (n = 34) endorsed significant levels of neuropathic pain. Severity of depression was moderately associated with neuropathic pain (r = 0.341, p < 0.004) but this relationship was confounded by levels of fatigue. Furthermore, only 40% of patients with moderate or severe depressive symptoms received antidepressant medical treatment. Fifty percent of those treated reported persistent moderate to severe depressive symptoms under treatment.Conclusions:Moderate and severe depression in patients with NMOSD is associated with neuropathic pain and fatigue and is insufficiently treated. These results are consistent across 2 research centers and continents. Future research needs to address how depression can be effectively managed and treated in NMOSD.

show abstract

“…Psychiatric disorders are evident not only in patients with MS, but also in patients with NMOSD, as observed in a Japanese cohort 68 and in a UK cohort. 69 These disorders include major depressive disorder during the lifetime (46% and 34%), suicidality (41% and 5%), agoraphobia (16% and 5%), panic disorder during the lifetime (14% and 11%) and manic episodes during the lifetime (11% and 0%) in patients with NMOSD and MS, respectively. 69 Significantly higher rates of recurrent depression and suicidality were present in patients with NMOSD than in patients with MS. 69 However, the neuropathological mechanisms of psychiatric disorders have remained unclear in patients with NMOSD.…”

Section: Spectrum Of Mood Disorders In Ms and Nmosdmentioning

confidence: 99%

Neuropathological features of “non‐motor” symptoms in multiple sclerosis and neuromyelitis optica

Kawachi

2019

Clinical & Exp Neuroim

View full text Add to dashboard Cite

Multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD) are the two main autoimmune demyelinating disorders of the central nervous system. MS is defined as autoimmune oligodendrocytopathy (unknown autoantigens), and NMOSD is defined as autoimmune astrocytopathy or aquaporin-4 channelopathy. Both diseases can occur throughout the central nervous system, and do often cause various "motor" and "nonmotor" symptoms. "Non-motor" symptoms, including cognitive impairment, fatigue, pain and neuropsychological symptoms (e.g. depression, loneliness and anxiety), have gained renewed attention in MS and NMOSD since the past three decades, because they influence a patient's competence in daily life activities, including the participation in social activities and their employment status. Herein, we summarize the current concepts of the neuropathological processes of these "non-motor" symptoms in MS and NMOSD. These concepts help to define the novel disease-specific mechanisms of the two diseases, and to improve the quality of daily life of patients with MS and NMOSD.

show abstract

Cognitive and psychiatric comorbidities in neuromyelitis optica

Cited by 68 publications

References 38 publications

Cognitive impairment as one of the important non‐motor symptoms in multiple sclerosis and neuromyelitis optica spectrum disorders

Cognitive impairment as one of the important non‐motor symptoms in multiple sclerosis and neuromyelitis optica spectrum disorders

Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder

Neuropathological features of “non‐motor” symptoms in multiple sclerosis and neuromyelitis optica

Contact Info

Product

Resources

About